TOP > 外国特許検索 > PLURIPOTENT STEM CELL CARDIOMYOCYTE DIFFERENTIATION-PROMOTING AGENT

PLURIPOTENT STEM CELL CARDIOMYOCYTE DIFFERENTIATION-PROMOTING AGENT

外国特許コード F180009659
整理番号 2967
掲載日 2018年11月21日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP069054
国際公開番号 WO 2012026491
国際出願日 平成23年8月24日(2011.8.24)
国際公開日 平成24年3月1日(2012.3.1)
優先権データ
  • 特願2010-189548 (2010.8.26) JP
発明の名称 (英語) PLURIPOTENT STEM CELL CARDIOMYOCYTE DIFFERENTIATION-PROMOTING AGENT
発明の概要(英語) The present invention pertains to: a differentiation-promoting agent for pluripotent stem cell cardiomyocytes that contains the compounded represented by formula (1) or a salt thereof; a method for inducing differentiation into cardiomyocytes from pluripotent stem cells; and a method for producing cardiomyocytes.
従来技術、競合技術の概要(英語) BACKGROUND ART
The method for inducing differentiation of pluripotent stem cells, in vitro efficacy of regenerative medicine realizes a evaluation test, or a key role in the establishment of drug safety testing in. In particular, heart disease is the second current and causes the death of Japanese, regenerative medicine or heart disease efficacy is important for the evaluation. In addition to the heart arrhythmia and heart failure such as serious side effects from drugs often, cardiotoxicity test can be used in the uniform supply of heart muscle cells is demanded. Up to now, human ES cells to differentiate into heart cells one method, a mouse-derived feeder cells and human ES cells in co-culture of END2 cells have been reported a method (non-patent document 1). However, its differentiation efficiency is not sufficient, the END2 cells are human heart cells from mice for is likely, it is difficult to obtain pure human myocardial cells there is a problem. In addition, as another method, to form embryoid bodies from ES cells and, where several types of cytokines (fibroblast cell growth factor (bFGF), bone morphogenic protein 4 (BMP4), a vascular endothelial growth factor (VEGF), (DKK1) Dickkopf-1, activin A) was added and the, induced to differentiate into myocardial cells have been reported a method (non-patent document 2, 3). However, this method requires a large amount of cytokines is costly, the differentiation efficiency is not sufficient.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • Kyoto University
  • Stem Cell and Drug Discovery Institute
  • 発明者(英語)
  • NAKATSUJI, Norio
  • UESUGI, Motonari
  • YAMADA, Kouhei
  • MINAMI, Itsunari
  • OTSUJI, Tomomi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close